Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab for Refractory Myasthenia Gravis
NCT06836973Phase 3Not yet recruiting
- Start
- Apr 2025
- Primary completion
- Mar 2028
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
01
Overview
A Phase 3 trial of blinatumomab in myasthenia gravis (MG). Planned start Apr 2025; status: not yet recruiting.
02
Drugs
blinatumomab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06836973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06836973.